Pharm-Olam enrolls patients in Zealand Pharma orphan drug study

Pharm-Olam is now enrolling patients in the U.S. and Europe into a pivotal Phase III study within the treatment of short bowel syndrome. Initiated in early October 2018, the study is a placebo-controlled, randomized, parallel-group, double-blind clinical trial with fixed-dose injections. The trial is being conducted at approximately 40 investigational sites in the United States, Canada, and Europe and will ultimately enroll 129 patients with SBS. Because people with SBS often cannot absorb enough nutrients, the trial will help determine if parenteral support volume can be reduced. Zealand Pharma is developing a long-acting GLP-2 analog in an auto-injector with potential for convenient weekly administration, which has been granted orphan status by the U.S. Food and Drug Administration.

https://thefly.com/landingPageNews.php?id=2859065